The Application of Anti-inflammatory Agents in Prostate Cancer
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Nephrology & Urology".
Deadline for manuscript submissions: closed (31 December 2021) | Viewed by 7273
Special Issue Editor
Special Issue Information
Dear Colleagues,
Prostate cancer is the most common cancer in many countries resulting in many deaths. Biopsy specimens or prostatectomy specimens indicate the presence of innate and adoptive immune cells in the microenvironments of prostate cancers and recent studies have revealed that inflammation in the tumor microenvironment plays important roles in tumor progression. Cells that comprise the tumor microenvironment can act as a “friend or foe” with many contributing to local inflammation, thus making them potential targets for anti-cancer therapy. Systemic inflammation caused by diet or obesity also leads to prostate cancer progression. Drugs, such as non-steroidal anti-inflammatory agents and metformin, and diets that suppress the inflammatory responses or modulate immune status could have clinical benefits for prostate cancer patients. This Special Issue of the Journal of Clinical Medicine will cover topics regarding inflammation in prostate cancer, anti-inflammatory agents for the treatment of prostate cancer, chemoprevention of prostate cancer, with modulators of inflammation, and diets associated with promoting or suppressing inflammation in prostate cancer.
Dr. Kazutoshi Fujita
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
